BioNTech drops mid-stage trial of colorectal cancer mRNA vaccine; shares fall 8%

BNTX BioNTech SE ADR

$92.06 -3.35%

View chart & analysis →

1. 1BioNTech (BNTX) halts mid-stage trial of its mRNA vaccine as standalone treatment after colorectal cancer surgery... shares slump 8% on Friday
2. 2Independent safety board recommends termination, citing low likelihood of demonstrating efficacy... no new safety signals observed
3. 3BMO Capital calls it a 'clear setback'... mid-stage trial of Tecentriq combo in pancreatic cancer to proceed as planned

Source Barrons.com +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →